Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moxalactam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CMA1 | P23946 | 18/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxalactam SCHEMBL49017 | 0.78 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL49016 | 0.78 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL194012 | 0.78 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL14196602 | 0.78 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL194013 | 0.78 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL584454 | 0.77 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL951857 | 0.77 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL10694935 | 0.77 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL951858 | 0.77 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL9800360 | 0.77 | PTGS1 (0.97) | PTGS1HSD17B10TDP1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635536-A1 | PUNCTURE EXTENSION DEVICE | Clinicas Dr. Juan Cabrera, S.L. (ES) | 2025-10-22 | — | — | EP | claimed |
| US-20240001086-A9 | SYSTEMS, DEVICES, AND METHODS FOR TREATING A PULMONARY DISORDER WITH AN AGENT | INNOVATUS LIFE SCIENCES LENDING FUND 1, LP | 2024-01-04 | — | — | US | claimed |
| CN-116782865-A | Atomic layer deposition coated pharmaceutical packages, improved syringes and vials, e.g., for lyophilization/cold chain drugs/vaccines | SIO2医药产品公司 | 2023-09-19 | — | — | CN | claimed |
| US-20230075851-A1 | SYSTEMS, DEVICES, AND METHODS FOR TREATING A PULMONARY DISORDER WITH AN AGENT | NUVAIRA INC (US) | 2023-03-09 | — | — | US | claimed |
| EP-4695011-A1 | METHODS AND SYSTEMS FOR PREPARING SCLEROSANT FOAMS | Vascular Barcelona Devices, S.L. (ES) | 2026-02-18 | — | — | EP | disclosed |
| US-20260034520-A1 | METHODS AND SYSTEMS FOR PREPARING SCLEROSANT FOAMS | VASCULAR BARCELONA DEVICES S L (ES) | 2026-02-05 | — | — | US | disclosed |
| US-12496469-B2 | Devices and methods for endoluminal delivery of either fluid or energy for denervation | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250339823-A1 | METHODS, DEVICES, SYSTEMS AND PRODUCTS FOR PREPARING COMPOSITIONS FOR CARE AND REPAIR OF VARICOSE VEINS | VASCULAR BARCELONA DEVICES S L (ES) | 2025-11-06 | — | — | US | disclosed |
| WO-2025226786-A1 | METHODS AND COMPOSITIONS COMPRISING WETTABLE ELECTROSPUN MATRIX | POLY-MED, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4635536-A1 | PUNCTURE EXTENSION DEVICE | Clinicas Dr. Juan Cabrera, S.L. (ES) | 2025-10-22 | — | — | EP | disclosed |
| US-20250289909-A1 | FUNCTIONALIZED AND CROSSLINKED POLYMERS | PMIDG LLC (US) | 2025-09-18 | — | — | US | disclosed |
| EP-4166098-B1 | VASCULAR DRUG DELIVERY DEVICES | GORE & ASS (US) | 2025-09-17 | — | — | EP | disclosed |
| CN-107592807-B | Cycloolefin polymer container having a scratch-resistant and antistatic coating | SIO2医药产品公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3979947-A1 | METHODS, DEVICES AND COMPOSITIONS FOR LOCAL DELIVERY | Poly-Med Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11292640-B2 | Preparation of therapeutic foam | BTG INTERNATIONAL LIMITED | 2022-04-05 | — | — | US | disclosed |
| US-20220088137-A1 | METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES | JUVENESCENCE LIMITED (GB) | 2022-03-24 | — | — | US | disclosed |
| US-20220088138-A1 | METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES | JUVENESCENCE LIMITED (GB) | 2022-03-24 | — | — | US | disclosed |
| US-11273287-B2 | Selectively delivering particles into the distal portion of the left gastric artery | ENDOBAR SOLUTIONS LLC (US) | 2022-03-15 | — | — | US | disclosed |
| CN-114096213-A | Methods, devices and compositions for topical delivery | 聚合-医药有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-113577300-B | Targeted liposome drug delivery system and preparation method and application thereof | 首都医科大学附属北京儿童医院 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034520-A1 | METHODS AND SYSTEMS FOR PREPARING SCLEROSANT FOAMS | PF4, F10, VMP1 | PTGS1 343/4885HSD17B10 2115/4885TDP1 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.